The approval covers a six-month sustained-release version of Decapeptyl®, an LHRH agonist. Debiopharm and its European marketing partner, Ipsen, confirmed regulatory approval of its prostate cancer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback